

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1655CXW

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America
NEWS 5 AUG 30 CA/CAPLUS - Increased access to 19th century research documents
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 OCT 03 MATHDI removed from STN
NEWS 9 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added
to core patent offices
NEWS 10 OCT 06 STN AnaVist workshops to be held in North America
NEWS 11 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 12 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download
of CAPLUS documents for use in third-party analysis and
visualization tools
NEWS 13 OCT 27 Free KWIC format extended in full-text databases
NEWS 14 OCT 27 DIOGENES content streamlined
NEWS 15 OCT 27 EPFULL enhanced with additional content

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0; CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:14:56 ON 07 NOV 2005

=> file .biotech caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FILES 'MEDLINE, BIOTECHDS, EMBASE, BIOSIS, SCISEARCH, CANCERLIT, CAPLUS'
ENTERED AT 17:15:08 ON 07 NOV 2005
ALL COPYRIGHTS AND RESTRICTIONS APPLY. SEE HELP USAGETERMS FOR DETAILS.

7 FILES IN THE FILE LIST

=> s oligonucleotide and tissue-specific polynucleotide
L1 1 OLIGONUCLEOTIDE AND TISSUE-SPECIFIC POLYNUCLEOTIDE

=> d all

L1 ANSWER 1 OF 1 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
AN 2002-02454 BIOTECHDS
TI Identifying tissue (tumor)-specific polynucleotide overexpressed in
tissue of interest as compared to control tissue, for detecting cancer
cells in patient, comprises DNA microarray analysis or quantitative
polymerase chain reaction;
the use of tumor-specific protein, genetic subtraction, DNA
microarray, and quantitative polymerase chain reaction
AU Houghton R L; Dillon D C; Molesh D A; Xu J; Zehentner B; Persing D H
PA Corixa
LO Seattle, WA, USA.
PI WO 2001075171 11 Oct 2001
AI WO 2001-US10631 2 Apr 2001
PRAI US 2000-256592 18 Dec 2000; US 2000-194241 3 Apr 2000
DT Patent
LA English
OS WPI: 2001-626449 [72]
AB A method (M1) for identifying **tissue-specific
polynucleotide** (P) is claimed. (M1) involves performing a
genetic subtraction to identify pool of (P) from tissue of interest (TI),
performing DNA microarray analysis to identify first subset of
polynucleotides (SP1) at least 2-fold overexpressed in TI, and performing
quantitative polymerase chain reaction (PCR) analysis on SP1 to identify
second subset of (P). Also claimed are: identifying (M2) a subset of (P)
showing complementary tissue-specific expression profiles in a TI;
determining (M3) the presence of a cancer cell in a patient; monitoring
(M4) the progression of a cancer in a patient; a composition for
detecting a cancer cell in a biological sample; and a composition
containing an **oligonucleotide** primer or probe of between 15 and
100 nucleotides. The method is useful for determining the presence or
absence of a cancer cell in a patient, monitoring the progression of
cancer in a patient. (M1) to (M4) are useful for determining presence or
absence of or monitoring progression of prostate, mamma, colon, ovary,
lung, head and neck, lymphoma, leukemia, melanoma, liver, gastric etc.
cancer. (127pp)
CC THERAPEUTICS, Protein Therapeutics; DIAGNOSTICS, Molecular Diagnostis;
GENETIC TECHNIQUES AND APPLICATIONS, Gene Expression Techniques and
Analysis; BIOINFORMATICS AND ANALYSIS, Biochips and Bioarrays; DISEASE,
Cancer
CT MAMMA TUMOR-SPECIFIC PROTEIN IDENTIFICATION, GENETIC SUBTRACTION, DNA
MICROARRAY, QUANTITATIVE POLYMERASE CHAIN REACTION, TISSUE-SPECIFIC GENE
EXPRESSION PROFILING, DNA PROBE, DNA PRIMER, MONOCLONAL ANTIBODY, APPL.
COLON, OVARY, LUNG, HEAD NECK, LYMPHOMA, LEUKEMIA, LIVER, GASTRIC CANCER
THERAPY, DIAGNOSIS, MONITORING TUMOR DNA SEQUENCE PROTEIN SEQUENCE DNA
ARRAY DNA AMPLIFICATION (VOL.21, NO.4)